Table 1 Summary of antibodies, targets, drugs, and medications associated with PD1/PD-L1 immune checkpoint therapy

From: Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases

Antibody

Drug

Drug target

Indication

Comments

22C3 (Dako)

Pembrolizumab (Keytruda®); Merck

PD1

NSCLC, melanoma, HNSCC, urothelial, gastric/GEJ, CHL, MSI-H/dMMR

 

28-8 (Dako)

Nivolumab (Opdivo™); Bristol-Myers-Squibb

PD1

Advanced nsNSCLC, HNSCC, colorectal cancer (MSI-H/dMMR), melanoma, advanced liver cancer, CHL, advanced renal cancer, advanced urothelial cancer

Positive results = > 1%; nsNSCLC clinical results cutoffs at = > 1%; = > 5%; = > 10%

SP142 (Ventana)

Atezolizumab (Tecentriq™); Roche

PD-L1

Urothelial, NSCLC

 

SP263 (Ventana)

Durvalumab (Imfinzi®); AstraZeneca

PD-L1

Urothelial, advanced NSCLC in patients whose disease has not progressed following platinum-based CRT

 

73-10 (Dako)

Avelumab (Bavencio®); EMD Seronon/Pfizer

PD-L1

Merkel cell carcinoma, urothelial

Other tumor types in clinical trials

  1. CHL classic Hodgkin lymphoma; CRT chemo-radiation therapy; GEJ gastroesophageal junction; HNSCC head and neck squamous cell carcinoma; MSI-H/dMMR microsatellite instability–high/deleted mismatch repair; ns non-squamous; NSCLC non-small cell lung cancer
Back to article page